TY - JOUR
T1 - Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer
AU - Deek, Matthew P.
AU - Tran, Phuoc T.
N1 - Funding Information:
P.T.T. was supported by Ronald Rose & Joan Lazar; Movember Foundation, Prostate Cancer Foundation; Commonwealth Foundation; Barbara's Fund; and the National Institutes of Health/National Cancer Institute (U01CA212007, U01CA231776, and 1R21CA223403).
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging evidence suggesting metastasis-directed therapy can improve overall survival. Additionally, the use of stereotactic ablative radiation therapy within castration-sensitive oligometastatic prostate cancer cohorts appears to forestall the need to initiate systemic therapy, which has unfavorable side effect profiles, such as androgen deprivation therapy, while itself being associated with little toxicity. We review the literature surrounding the use of metastasis-directed therapy in the treatment of oligometastatic prostate cancer by reviewing the evidence for its use within 3 subgroups: de novo synchronous, oligorecurrent, and oligoprogressive disease.
AB - Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging evidence suggesting metastasis-directed therapy can improve overall survival. Additionally, the use of stereotactic ablative radiation therapy within castration-sensitive oligometastatic prostate cancer cohorts appears to forestall the need to initiate systemic therapy, which has unfavorable side effect profiles, such as androgen deprivation therapy, while itself being associated with little toxicity. We review the literature surrounding the use of metastasis-directed therapy in the treatment of oligometastatic prostate cancer by reviewing the evidence for its use within 3 subgroups: de novo synchronous, oligorecurrent, and oligoprogressive disease.
KW - Metastasis-directed therapy
KW - oligometastatic
KW - oligoprogressive de novo metastatic disease
KW - oligorecurrent
KW - prostate cancer
KW - stereotactic ablative radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85082261584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082261584&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000432
DO - 10.1097/PPO.0000000000000432
M3 - Review article
C2 - 32205538
AN - SCOPUS:85082261584
VL - 26
SP - 137
EP - 143
JO - Cancer journal (Sudbury, Mass.)
JF - Cancer journal (Sudbury, Mass.)
SN - 0765-7846
IS - 2
ER -